Back
Speaker illustration

Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

Member of:

Heart Failure Association

Presentations

Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Event: Heart Failure 2023

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Heart failure with preserved ejection fraction (HFpEF) 3

Access
Like
Thumbnail

Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial

Event: Heart Failure 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic heart failure - epidemiology, prognosis, outcome 2

Access
Like
Thumbnail

Cardio-renal-metabolic overlap, outcomes, and treatment with dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

Event: Heart Failure 2023

Topic: Comorbidities

Session: Chronic heart failure - comorbidities

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources